Institute Of Cancer Research, United Kingdom

This study tests whether adding a new drug called SX-682 to the standard drug apalutamide can help men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will enroll 78 men and aims to find a safe, effective dose and see i…

This trial tests two drugs, avutometinib and defactinib, alone or with a third drug (temozolomide), in people with aggressive brain tumors like glioblastoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 182 adults with recurrent …

This study tests whether injecting a very dilute hydrogen peroxide solution into breast tumors can make standard radiotherapy work better. It is for people with advanced or returning breast cancer who need radiation. The treatment, called KORTUC, is given twice a week during radi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumours, including cervical and triple-negative breast cancer. The goal is to see if blocking certain proteins can make cancer cells die in a way that tri…

This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can slow tumour growth. About 64 adults will take part, and researchers wil…

This study tests whether adding a combination of antibiotics to the standard drug enzalutamide can help men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 39 participants will receive the antibiotics for four weeks alongside enzalutamide…

This study aims to see if a type of PET-CT scan called FCH-PET-CT is better than standard scans (bone scan and MRI/CT) at finding cancer that has spread outside the pelvis in men with prostate cancer who have certain inherited gene mutations (like BRCA). About 50 men with these m…

This study follows over 4,000 men with prostate cancer to see if those with rare gene mutations (like BRCA) have different outcomes than those without. Researchers collect medical records and tumor samples to compare survival and cancer progression. The goal is to learn how these…

This study follows 200 men with prostate cancer who are on active surveillance (monitoring instead of immediate treatment). It compares those with higher genetic risk to those with average risk to see how their cancer changes over time. The goal is to learn whether genetic factor…

This study is testing a new saliva-based DNA test called i4i PRODICT® to see how well it can estimate a person's future risk of prostate cancer. The test looks at both common and rare genetic changes. Researchers aim to recruit 1,000 men aged 40-55 from Black, South Asian, and Wh…

This study looks at whether a genetic test can help doctors better assess prostate cancer risk in men who either have the disease or are at high risk. Researchers will analyze DNA from 3,000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see…